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a b s t r a c t
Background and objectives: Thymidylate synthase (TS) expression levels appear to be related to response
to 5-fluorouracil-(5-FU)-based chemotherapy in colorectal cancer (CRC) patients. Three polymorphisms
have been proposed as modulators of TS expression: a tandemly repeated sequence (2R/3R) in the 5′ UTR,
a SNP (G > C) within the 3R allele and a 6 bp deletion in the 3′ UTR.
To evaluate the influence of TS expression and polymorphisms on clinical outcome of 5-FU-treated
patients we performed a comprehensive genetic analysis on 63 CRC patients.
Methods: TS expression levels were analyzed in normal and tumor tissues. TS coding sequence and UTR
polymorphisms were investigated on DNA from normal tissue. LOH analysis was performed to determine
tumor genotype.
Results: A difference in disease-free survival (DFS), although not statistically significant, was observed
between high and low mRNA expression levels: patients with low levels showed longer DFS. The 2R2R
genotype showed significantly lower expression than the 3R3R and 2R3R genotypes in normal tissue. No
other TS polymorphism was associated with mRNA expression or clinical outcome.
′Conclusions: The results obtained in this pilot study indicate that the number of 5 UTR repeats is the
major genetic determinant of TS expression. The lack of association with other polymorphisms might
be partially explained by the existence of linkage disequilibrium in the TS gene. Our data support the
growing evidence that TS control may require multiple mechanisms acting in close coordination with
one another and suggest that TS genotyping alone in tumor samples is not sufficient to accurately predict
response to 5-FU.. Introduction
More than 50 years after its introduction into clinical practice,
-fluorouracil (5-FU) is still a fundamental drug in the treatment
f colorectal cancer (CRC) and many other tumors, either alonePlease cite this article in press as: Vignoli M, et al. Thymidylate synthase ex
of colorectal cancer patients treated with 5-fluorouracil. Pharmacol Res (2
r in combination with other drugs [1,2]. Several variables associ-
ted with genes involved in the 5-FU metabolic pathway have been
tudied for their potential relationship with clinical outcome and
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response to chemotherapy. To date the most widely studied molec-
ular marker is thymidylate synthase (TS), the biological target of
5-FU and related drugs. TS is the key enzyme of the de novo syn-
thesis of deoxythymidine monophosphate (dTMP), that catalyzes
the methylation of deoxyuridine monophosphate to dTMP [3,4], an
essential step in DNA synthesis.
The expression level of the TS gene appears to be related to clin-
ical outcome and response to 5-FU chemotherapy and has been
suggested as a potential prognostic and/or predictive marker. John-
ston et al. [5] first demonstrated a correlation between low TS
levels and improved 5-year disease-free survival (DFS) and over-pression and genotype have no major impact on the clinical outcome
011), doi:10.1016/j.phrs.2011.04.006
all survival (OS) in rectal cancer patients receiving 5-FU adjuvant
chemotherapy. A meta-analysis by Popat et al. [6] showed that CRC
patients with advanced disease treated with TS inhibitors had a sig-
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r metastases, whereas a predictive role of TS expression was not
stablished for the adjuvant setting.
Three different polymorphisms in the TS untranslated regions
UTRs) have been proposed as modulators of TS mRNA transcrip-
ional and translational efficiency. The 5′ UTR contains a variable
umber of 28 bp tandem repeats (VNTR) [7,8]. Although up to nine
epeats have been described, the vast majority of TS alleles har-
or either 2 or 3 repeats, creating genotypes defined as 2R/2R,
R/3R and 3R/3R, respectively. The 3R alleles present a G > C single
ucleotide polymorphism (SNP) at the 12th position of the second
epeat [9]. The two alleles of this SNP are defined as 3RG and 3RC,
espectively. The third polymorphism is a 6 bp insertion/deletion at
ucleotide 1494 within the 3′ UTR [10]. In addition, a further SNP in
he VNTR region, consisting of a C > G substitution in the first repeat
f the 2R allele, has recently been described [11].
Many studies have been conducted to investigate whether TS
enotypes might explain differences in mRNA expression levels,
ut the results are heterogeneous and even controversial.
In vitro experiments have shown that the 3R/3R genotype is
ssociated with higher levels of TS gene expression than the 2R/2R
enotype [8]. Subsequent experiments on DNA samples from CRC
atients provided support to these results, indicating that the 3R
equence has greater transcriptional efficiency than the 2R allele
12,13]. The influence of the VNTR on TS expression has been
scribed to the presence of a USF family E-box consensus element
n repeat units containing the G nucleotide at position 12. The G > C
ubstitution eliminates the USF-1 binding site, thus abolishing the
ranslation enhancer effect of the 3R allele [9]. Each of the first two
epeats of the 3RG allele has a G at this position; therefore, 3RG
lleles contain two potential USF-1 binding sites, whereas the G is
resent only in the first repeat of 2R and 3RC alleles, that conse-
uently have a single USF-1 site.
The ins/del polymorphism within the 3′ UTR seems to modulate
S expression by affecting mRNA stability; the 6bpdel allele has
een associated with decreased mRNA stability in vitro and lower
ntratumoral TS expression in vivo [14,15].
By contrast, other studies did not detect any correlation between
S polymorphisms and mRNA or protein expression levels [16–18],
r even a significantly decreased TS mRNA expression in samples
rom patients with the 3R/3R genotype [19].
Discrepancies in results among different studies may be due
o methodological differences or incomplete analysis leading to
artial results. Some groups analyzed TS expression levels by
mmunohistochemistry (IHC) [14,15,20] while others used real
ime quantitative PCR [12,21,22]. In addition, loss of heterozygosity
LOH), that modifies TS genotype in tumor cells, has been reported
o affect tumor response and survival and TS expression [21,23].
In order to take into account all major intrinsic factors poten-
ially involved in the relationship between TS genotype, expression
nd clinical response to 5-FU, we performed a comprehensive pilot
tudy; this involved investigation of the whole TS coding sequence,
′ and 3′ UTR polymorphisms and mRNA expression in normal
nd matching tumor tissues of a series of CRC patients receiv-
ng treatment with 5-FU only. We analyzed possible associations
etween TS genotype and expression as well as those between
hese experimental data and survival parameters (DFS and OS).
dditional associations between TS genotype, expression and clin-
cal/pathological characteristics were explored.
. Materials and methodsPlease cite this article in press as: Vignoli M, et al. Thymidylate synthase ex
of colorectal cancer patients treated with 5-fluorouracil. Pharmacol Res (2
.1. Tissue samples
Primary tumor and corresponding colonic mucosa explants
btained from 63 CRC patients at surgery were frozen in liquid PRESS
esearch xxx (2011) xxx–xxx
nitrogen until molecular analysis. Normal colonic mucosa was
taken at a distance of ∼10 cm from the tumors. Immediately after
resection, the tumor sample was divided into equal portions after
washing and removal of necrotic tissues. Some specimens were
fresh frozen in liquid nitrogen, and one portion was embedded
in paraffin to confirm histologically that it was not significantly
contaminated by normal or necrotic tissue, or lymphocytes.
All samples were collected before combination chemotherapy
became standard practice both in the adjuvant setting and for
advanced disease in CRC patients. Patients treated in the adjuvant
setting received folinic acid and 5-FU according to the sched-
ule described in the pooled analysis by the IMPACT investigators
[24]. Patients treated for advanced disease received chemotherapy
according to the Machover regimen [25]. In both cases high-dose
folinic acid was administered.
Informed consent was obtained from all patients for the use
of specimens and clinical/pathological data for research purposes
according to the guidelines established by the local ethical com-
mittee.
2.2. Gene expression analysis
Total RNA was isolated from tumor and normal tissues using
a Trizol RNA isolation kit with glass-fiber filter purification
methodology (RiboPure kit, Ambion Inc., Austin, TX, USA). RNA
concentration and purity were verified by a Gene Quant II spec-
trophometer (Pharmacia Biotech, Cambridge, UK).
cDNA was generated from 10 g of total RNA using random
primers and the M-MLV reverse transcriptase RNase H minus
(Promega Corporation, Madison, WI, USA) according to the man-
ufacturer’s protocol.
Real-time polymerase chain reaction (RT-PCR) analysis was
performed with the ABI PRISM 7900HT Fast Sequence Detection
System (Applied Biosystems, Foster City, CA, USA).
A predesigned and validated gene-specific probe-based TaqMan
Gene Expression Assay from Applied Biosystems (Foster City, CA,
USA) was used for the TS gene. Reactions were performed using
Taqman Fast Universal PCR Master Mix No AmpErase UNG; two to
three replicates for each reaction were plated onto 96-well plates.
The PCR program was 95 ◦C for 20 s and 40 cycles of 95 ◦C for 1 s
and 60 ◦C for 20 s.
The housekeeping gene glyceraldehyde 3-phosphate dehy-
drogenase (GAPDH) was used as endogenous reference for
standardization (TaqMan Endogenous Control concentration-
limited primer, Applied Biosystems, Foster City, CA, USA), and the
Human Reference Total RNA (Stratagene, La Jolla, CA, USA) was used
as a calibrator sample. The expression levels of TS mRNA were nor-
malized to the endogenous reference and expressed relative to the
calibrator as 2−CT, according to the comparative CT method [26].
A validation experiment was performed to demonstrate that the
efficiencies of TS and reference gene amplifications were approxi-
mately equal, using a standard curve method with several dilutions
of the cDNA calibrator sample.
2.3. TS genotyping
Genomic DNA extraction was performed using BIOROBOT EZ1
(Qiagen, Italy) and EZ1 DNA Tissue Kit (Qiagen, Italy) according to
the manufacturer’s protocol.
In order to detect rare coding sequence variations, genomic
DNA samples were screened by denaturing high-performancepression and genotype have no major impact on the clinical outcome
011), doi:10.1016/j.phrs.2011.04.006
liquid chromatography (dHPLC) on a Transgenomic Wave Sys-
tem (Transgenomic Co., Omaha, NE, USA). Primers and conditions
used for PCR amplification and dHLPC analysis are available upon
request.
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Amplification of the 5′ UTR tract containing the VNTR and G > C
NP was performed as previously described [22]. PCR products
ere electrophoresed onto a 2.5% agarose gel. Amplification prod-
cts of 213 and 241 bp were observed for the 2R and 3R alleles,
espectively. Ten microliters of the amplification products from all
amples were subsequently digested with the restriction enzyme
aeIII, which allows recognition of the G/C SNP in the 3R allele.
aeIII digestion also allows to investigate the C/G SNP located in
he proximal repeat of the 2R allele. Digested PCR products were
lectrophoresed onto non-denaturing polyacrylamide gels.
For 1494del6 bp analysis, genomic DNA was amplified by
CR using the following primers: forward 5′-CAAATCTGAGG-
AGCTGAGT, reverse 5′-TGAGCAGATAAGTGGCAGTACA in a reac-
ion containing 100 ng DNA, 1.5 mM MgCl2, 0.25 mM deoxynu-
leotide triphosphates, 30 pmol of each primer and 1.25 U of Taq
olymerase. Cycling conditions were: denaturation at 95 ◦C for 30 s,
nnealing at 60 ◦C for 30 s and elongation at 72 ◦C for 30 s, for 35
ycles. The amplified fragments were digested with DraI and the
roducts separated on a 2.5% agarose gel. The expected fragment
izes were 92 bp + 60 bp for the common allele (6bpins) and 146 bp
or the rare one (6bpdel).
LOH was investigated by comparing genotypes of matched
umor and normal tissue from the same patient. Patients homozy-
ous for the VNTR, G > C and 6 bp deletion polymorphisms were
nalyzed for other microsatellite markers located upstream and
ownstream of the TS gene region (D18S170, D18S1140, D18S1372,
18S498, D18S59). Primers were labelled with 6-FAM to allow
etection of the amplified products by an ABI Prism 310 Genetic
nalyser. LOH was determined by assessment of peak height ratios
etween tumor and constitutional alleles using the following for-
ula:
constitutional allele 2/constitutional allele 1
tumor allele 2/tumor allele 1
.
A ratio >1.5 indicated loss of allele 2, a ratio <0.5 indicated loss
f allele 1, and a ratio between 0.51 and 1.49 indicated retention ofPlease cite this article in press as: Vignoli M, et al. Thymidylate synthase ex
of colorectal cancer patients treated with 5-fluorouracil. Pharmacol Res (2
oth alleles.
LOH analysis could be performed on 60 out of 63 patients
ecause of unavailability of two tumor DNA samples and due
o the presence of microsatellite instability, that prevented LOH
ig. 1. Relationships between TS expression and 5′ UTR polymorphisms in normal tiss
= 0.049; 2R3R vs 3R3R, p = 0.322); (B) Relationship with complete 5′ UTR haplotype (VNT
, median value.a In brackets: numbers of USF-1 binding sites for each allele comprised in the
genotype combination.
assessment, in a third sample. Samples showing LOH were defined
as 2R/loss and 3R/loss to indicate the allele that was retained in
tumor DNA.
2.4. Statistical analysis
The correlations between TS mRNA expression in tumor and
normal tissue and clinical/pathological characteristics (sex, histo-
type, tumor site, stage and grading) and genotypes were analyzed
using ANOVA and t-test. The association between genotypes and
clinical/pathological features was analyzed by the 2 test.
In order to evaluate the relationships between response to ther-
apy and genotypes or pathological characteristics, patients were
categorized as responders or non responders on the basis of their
disease-free and disease recurrence status, respectively, and the 2
test was used.
The paired Student’s t-test was used to analyze the correlation
of TS gene expression between normal and tumor tissues.
5′ UTR TS genotypes were grouped according to the number
of USF-1 binding sites (Table 1). Comparisons were performed
between patients with 1–2 USF-1 TS binding sites and with 3–4
USF-1 TS binding sites for both normal and tumor tissue.pression and genotype have no major impact on the clinical outcome
011), doi:10.1016/j.phrs.2011.04.006
Genotypes of the 3′UTR were also considered, alone and in com-
bination with 5′ genotypes. The presence of linkage disequilibrium
(LD) between 5′ and 3′ UTR TS polymorphisms was investigated
ue. (A) Relationship with VNTR number (2R2R vs 3R3R, p = 0.020; 2R2R vs 2R3R,
R number and G > C SNP; 2 USF-1 binding site vs 3–4 USF-1 binding sites, p = 0.258);
ARTICLE IN PRESSG ModelYPHRS-2300; No. of Pages 7
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Table 2
Main clinical/pathological features of colorectal cancer patients.
























































Constitutional and tumor TS genotypes in colorectal cancer patients.
Constitutional genotype (%)a Tumor genotype (%)b
5′ UTR
2R/LOH – 9 (15)
2R2R 11 (17) 9 (15)
2R3R 30 (48) 12(20)
2R3RC 14 7
2R3RG 16 5
3R/LOH – 20 (33)
3RC – 8
3RG – 12





6bpdel/LOH – 12 (20)
6bpins/LOH – 17 (28)
6bpdel/6bpdel 15 (24) 7 (12)
6bpins/6bpins 22 (35) 12 (20)
6bpdel/6bpins 26 (41) 12 (20)
a n = 63.
between high and low tumor TS mRNA expression levels in the
group of patients with completely resected tumors (Fig. 3): patients
with low TS mRNA levels had a longer DFS (p = 0.122). On the otherAdjuvant 52
Palliative 11
sing MIDAS software [27]; D′ values >0 indicate the presence of
D.
Patients were divided into high and low TS mRNA level groups
sing the median value as a cut-off. Patients who died due to causes
nrelated to colorectal cancer were excluded. OS was calculated
rom surgery to the date of last follow-up or death, DFS from surgery
o the first evidence of disease. Median follow-up time was com-
uted for all patients alive at the time of analysis. Survival curves
ere estimated by the Kaplan Meier method and compared with
he log-rank test.
Analyses were carried out using the SPSS version 15 Software. P
alues <0.05 were considered significant.
. Results
Clinical/pathological characteristics of the patients investigated
re reported in Table 2. The series was comprised of 32 males and 31
emales, with a median age at diagnosis of 61 years (range 23–76).
ll patients received 5-FU chemotherapy: 52 as adjuvant and 11 as
alliation.
Interindividual variation in TS mRNA expression was 25.5
TS/GAPDH ratios: 0.35–8.93; median value 1.53) and 231.5 fold
TS/GAPDH ratios: 0.04–9.26; median value 1.93) in tumor and nor-
al tissue, respectively (data not shown). However, overall, mean
S mRNA expression was not significantly different between tumor
nd normal tissue (p = 0.076, mean ± SD: 1.96 ± 1.82 vs 2.67 ± 2.27,
espectively).
Genotype distributions of the VNTR, G > C SNP, ins/del 6 bp poly-
orphisms and their combinations in tumor or normal tissue are
hown in Table 3. LOH was found in 29/60 (48%) samples. The
ecently described C > G SNP in the first repeat of the 2R allele was
bsent in this series. Genotype frequencies of the 5′ VNTR and 3′
bp deletion polymorphisms were within Hardy–Weinberg equi-
ibrium (data not shown). Analysis of allelic combinations at these
ites showed the presence of LD: the 3RG allele was associated with
he 6bpdel allele in the 3′ UTR (D′ = 0.68) and, on the other hand,
he 2R allele was associated with absence of 6bpdel (D′ = 0.67).Please cite this article in press as: Vignoli M, et al. Thymidylate synthase ex
of colorectal cancer patients treated with 5-fluorouracil. Pharmacol Res (2
No sequence variation was found within the TS coding sequence
y extensive dHPLC screening.
The VNTR genotype was associated with TS expression levels
n normal tissues, with the 2R2R genotype showing significantlyb n = 60 (tumor genotype was not analyzed in 3 patients due to unavailability of
DNA from tumor tissue).
lower mRNA expression than the 3R3R and 2R3R genotypes
(p = 0.020 and 0.049, respectively; Fig. 1a). However, there was
no significant association in normal colonic mucosa between TS
expression and the complete 5′UTR genotypes (VNTR combined
with the G > C SNP), when these were divided into 2 groups cor-
responding to the presence of 2 and 3–4 USF-1 binding sites,
respectively (Fig. 1b).
No other relationship was observed between genotype and TS
expression levels either in normal or tumor tissue. In particular, TS
expression levels were similar between tumor samples with 1–2
and 3–4 USF-1 binding sites (Fig. 2).
Although not significant, a difference in DFS was observedpression and genotype have no major impact on the clinical outcome
011), doi:10.1016/j.phrs.2011.04.006
Fig. 2. Relationship between TS expression and 5′ UTR genotype (VNTR and G > C
SNP) in tumor tissues (1–2 USF-1 binding site vs 3–4 USF-1 binding sites, p = 0.626);
—, median value.
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Fig. 3. Survival parameters of patients who received 5-FU chemotherapy according




















been observed [32]. This latter observation is consistent with the
experimental results that provided original evidence for a role of
F
d
S mRNA expression >1.53 (median value); n = 52, p = 0.122.
and, no difference was observed between survival parameters (OS
nd DFS) and TS expression in normal tissue (data not shown).
Combined analysis of TS VNTR and G > C genotypes both in nor-
al and tumor tissue showed that completely resected patients
n = 52) with 1–2 USF-1 binding sites had a prolonged survival
ompared to patients with 3–4 USF-1 binding sites. However this
ifference was not statistically significant (Fig. 4). Similarly, no sig-
ificant difference was observed when OS was evaluated in the
ntire case series (n = 63) (data not shown).
Evaluation of TS 3′ UTR polymorphism alone or in combination
ith the 5′ UTR genotype did not show any significant difference
n relation to survival parameters (data not shown).
No relationship was observed between clinical/pathological fea-
ures and TS expression levels either in normal or tumor tissues.
ikewise, no correlation between allele and genotype frequencies
n the 5′ or 3′ UTR, including repeat number in the VNTR, G > C
NP and 6 bp deletion polymorphisms, and clinical/pathological
eatures were observed (data not shown).
Finally, no association between clinical features/TS geno-
ypes/TS expression and response to therapy was observed, withPlease cite this article in press as: Vignoli M, et al. Thymidylate synthase ex
of colorectal cancer patients treated with 5-fluorouracil. Pharmacol Res (2
he exception of a statistically significant value (p = 0.007) between
uke’s stage and response: patients with Duke’s stage B had a
ig. 4. Overall survival according to the number of USF binding sites in the TS 5′UTR obs
ata; n = 49, p = 0.162) (B) of CRC patients. PRESS
esearch xxx (2011) xxx–xxx 5
lower incidence of disease recurrence (47.8%) compared to stage
C patients (69.3%).
4. Discussion
In the present study we have extended our previous analy-
sis of the relationship between TS genotype, TS mRNA levels, and
response to 5-FU treatment in CRC patients [22]. To this purpose,
we investigated expression and genotypes in both normal colonic
mucosa and tumor tissue and we analyzed further genetic variables,
including the whole TS coding sequence in constitutional DNA, LOH
in the TS region, 3′ UTR polymorphisms, and estimate of LD.
Overall, no significant correlations between TS alleles, genotypes
or expression, and clinical parameters, including response to 5-FU,
were observed. Although the difference was not statistically signifi-
cant, results on the relation between survival and TS expression are
in keeping with those obtained in our previous study [22] as well
as by other authors [5,12,28,29]: patients with low TS expression
levels tend to have a prolonged DFS compared to those with high
TS expression levels in tumor tissue.
Since both in vitro and in vivo data indicate that intragenic
polymorphisms may influence TS expression levels [8,9,12,30], we
investigated potential genotype/mRNA correlations in this series.
Among the different intragenic TS variants analyzed, a significant
association was only found between 5′ UTR 28 bp repeat number
and TS mRNA expression in normal, but not in tumor, tissue. The
intrarepeat G > C SNP apparently did not have a major influence
on the effects of repeat numbers, since no difference was observed
when complete 5′ UTR genotypes were assessed against expression,
clinical characteristics, survival and response to 5-FU treatment.
Since the influence of the VNTR on TS expression has been
attributed to the presence of one USF family E-box consensus ele-
ment in repeat units containing the G nucleotide, we classified TS 5′
UTR genotypes according to the number of USF-1 binding sites. The
absence of a significant correlation between complete 5′ UTR geno-
type and clinical parameters indicates that the number of USF-1
sites does not have a major influence on survival.
These findings suggest that the number of repeats could be more
important than their sequence differences for the regulation of TS
mRNA expression in vivo. Other authors reported similar results,
confirmed both at the RNA and protein level, on CRC tissue samples
[31]. On the other hand, a positive correlation between TS protein
expression/activity and the 3RG allele in normal mucosa has alsopression and genotype have no major impact on the clinical outcome
011), doi:10.1016/j.phrs.2011.04.006
the G > C SNP on TS transcriptional efficiency [9]. It has also recently
been suggested that the position of the G nucleotide in the repeat
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luster may be important for transcriptional efficiency: its loca-
ion in the most 5′ repeat has been found to be associated with
igh expression levels, regardless of the presence of additional G-
ontaining repeats [33]. However, while in vitro studies are very
mportant to understand the pathophysiological mechanisms of TS
egulation, they may not reflect more complex in vivo conditions,
ince the regulation of TS expression is likely dependent on multiple
is and trans factors.
The apparently contrasting results on the effects of VNTR repeat
umber and TS mRNA expression obtained in mucosa and tumor
amples could be related to the occurrence of somatic mutations
nd epigenetic alterations involving TS as well as additional loci
mplicated in the control of TS expression in tumor cells. Deletions
f chromosome 18 are a frequent event in colorectal carcinogenesis
nd, when they involve the TS locus, they can cause a reduction in
ts expression levels. So far, most studies analyzing TS prognostic
nd predictive role have not considered the possible occurrence of
OH in tumor cells. In addition, while most previous studies limited
OH analysis to cases that were heterozygous for one of the three
S intragenic polymorphisms [17,21,23,34], we investigated flank-
ng extragenic polymorphisms in order to increase the number of
nformative samples. Overall, the results obtained indicate that LOH
lone cannot account for the different correlations between geno-
ype and RNA expression observed in normal and tumor tissue, and
hat other factors are implicated in the control of TS expression in
RC cells.
The lack of any association between individual and combined
S polymorphisms and clinical outcome following 5-FU treatment
n this series of CRC patients is in accordance with the results
f recent studies [35,36]. Other studies have reported contrast-
ng results on the clinical significance of the three common UTR
S polymorphisms [16,17,37,38]. It should be considered that some
uthors assign high and low expression levels to the 3R3R and 2R2R
enotype, respectively, on the basis of previously published data
35–38]. However, these assignments may not be correct, since we,
s well as other authors [16,17], have observed that TS expression
evels do not correlate with TS genotype.
In general, expression and survival analyses in relation to geno-
ype are complicated by the presence of multiple TS polymorphisms
hat occur in different haplotype combinations containing alleles
ith either synergic or opposite consequences on TS mRNA levels.
he existence of LD, documented by us and other authors [14,35],
ay partially explain the discrepancies between results obtained
n vitro and on clinical samples. Since the 3RG allele is associated
ith the 3′ 6 bp deletion, that is thought to reduce mRNA stability,
he overall effect should depend on the interaction between these
ariants. The same applies to other TS haplotype combinations.
Rare DNA variants in the TS coding sequence may also influ-
nce the effects of the UTR polymorphisms [39]. However, none of
he patients included in this study, that is the first one to screen
he whole TS coding sequence for prognostic purposes, showed
lterations.
Furthermore, TS transcription and translation are likely influ-
nced by other genes, whose sequence (e.g. p53) [40] and
xpression (e.g. AEG-1) [41] can be altered in tumor tissues. It has
een suggested that the p53 status could play a role in TS expres-
ion in tumor cells, by altering transcription and/or translation
evels [40]. It has also been shown that astrocyte elevated gene-1
AEG-1), known to augment invasion, metastasis and angiogenesis,
irectly contributes to 5-FU resistance, since it induces the expres-
ion of LSF (late SV40 factor), a transcription factor that regulates
he expression of TS [41].Please cite this article in press as: Vignoli M, et al. Thymidylate synthase ex
of colorectal cancer patients treated with 5-fluorouracil. Pharmacol Res (2
The TS protein has also been shown to inhibit the translation
f TS mRNA in an autoregulatory manner [42], suggesting that TS
enotyping alone is not sufficient to accurately predict response
o 5-FU. It is also likely that other genes coding for enzymes or PRESS
esearch xxx (2011) xxx–xxx
proteins involved in the mechanism of action and in the inactivating
or activating metabolism of 5-FU are involved in the outcome of
colorectal cancer patients treated with 5-FU [43].
It has also been observed that an increase in the intracellular
pool of reduced folates following exposure to folinic acid enhances
5-FU antitumor activity [44,45]. This is due to an increased inhi-
bition of TS enzyme activity via the formation of a covalent
ternary complex among the active 5-FU metabolite 5-fluoro-
2’-deoxyuridine-5’-monophosphate, TS and the 5,10-methylene
tetrahydrofolate cofactor [3,4,46]. This ultimately leads to greater
sensitivity to 5-FU [47] and improves response rate and overall
survival in colorectal cancer patients compared with 5-FU alone
[48]. Different size and composition of cellular folate cofactor pools
may thus be another important factor of variability to 5-FU treat-
ment. The use of high-dose folinic acid in our case series [24,25]
potentially allowed maximal enhancement of clinical 5-FU anti-
tumor activity. However, interindividual variability in the size and
composition of cellular folate pools, possibly mediated by polymor-
phisms of folate transporters or metabolic enzymes (e.g. MTHFR)
[49] may have occurred in our series. This aspect was not studied
and warrants further investigation on larger series.
In conclusion, we did not find significant correlations for most
parameters evaluated in this study, despite comprehensive analy-
sis of TS gene variants and RNA expression in both normal colonic
and tumor tissue. However, due to the relatively limited sample
size, weak effects of additional genotypic variations cannot be com-
pletely excluded. Further investigations on larger sample series are
needed to clarify whether TS has a relevant role in determining
response to FU treatment and can be used in the clinical setting.
Methodological issues related to quantitation of TS RNA, protein
expression and enzyme activity, as well as the potential involve-
ment of additional constitutional and acquired genetic factors will
also need to be addressed.
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